Evogene and QUT partner on AI-based cancer therapies
Evogene has partnered with Queensland University of Technology (QUT) in Australia to progress the development of AI-driven small molecule cancer …
Post
-
-
The China factor: US pharma group campaigns for increased competitiveness
In the race to lead the innovation narrative, the US healthcare industry needs to actively consider systemic changes to contend …
-
J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC
Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for a new monthly dosing schedule for …
-
SLE and LN market expected to reach $5.9bn across 7MM by 2034
A notable growth in the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets (7MM; …
-
RNA-targeting small molecules: a new frontier of drug discovery
While small molecules have long been the cornerstone of the pharmaceutical industry, there is increasingly a demand for innovative precision …
-
Pricing and reimbursement delays continue to impact biopharma revenue streams
Delays in obtaining pricing and reimbursement (P&R) have been identified as key hurdles holding back the pharmaceutical industry, according to …
-
Pharma companies venture further afield in search of R&D
With manufacturing onshoring a continuing point of discussion in the industry, many pharma companies went the opposite way for R&D …
-
Teijin and Aska Pharmaceutical to co-develop gynaecological drugs
Teijin Pharma has signed a joint research agreement with Tokyo-based Aska Pharmaceutical to develop small-molecule drug candidates for gynaecological diseases. The …
-
ExCellThera secures German NUB Status 1 listing for Zemcelpro
ExCellThera and its wholly owned subsidiary Cordex Biologics have received a Status 1 listing from the Neue Untersuchungs- und Behandlungsmethoden …
-
Eli Lilly builds orforglipron cache to avoid previous GLP-1RA shortages
In a bid to avoid previous shortages of injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs), Eli Lilly has already started to …
-
PTC pulls Translarna NDA after unfavourable FDA feedback
PTC Therapeutics has chosen to withdraw its resubmitted new drug application (NDA) for Duchenne muscular dystrophy (DMD) therapy, Translarna (ataluren), …
-
OEB 6: The new standard in high-potent molecule manufacturing?
In recent years, the pharmaceutical industry has seen a significant increase in the development of highly potent active pharmaceutical ingredients …
-
FDA issues complete response letter to Disc Medicine’s bitopertin NDA
Disc Medicine has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) concerning its new …
-
Immunic secures $400m fund to support commercial-stage development
Immunic has announced an oversubscribed private placement of up to $400m, strengthening its move from an R&D-focused organisation into a …
-
Theranostics earmarked as “the future” of radiopharmaceuticals
As the oncology market enters a new era of growth, targeted therapies across several modalities are transforming the treatment paradigm. …
